Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534727 | 0.82 | NPC1 (0.65) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL4033719 | 0.82 | NPC1 (0.65) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL6416826 | 0.82 | CA1 (0.48) | CA1CA2CA5ASPPL2ACTSK | |
| SCHEMBL5263402 | 0.81 | SIGMAR1 (0.51) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL6414189 | 0.81 | SIGMAR1 (0.51) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL2985968 | 0.81 | ALDH1A1 (0.52) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL1825379 | 0.80 | P2RX7 (0.54) | CA1CTSKGAACTSLCTSS | |
| SCHEMBL14396307 | 0.80 | BCHE (0.51) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL14396308 | 0.80 | BCHE (0.51) | ATMCTRB1NPC1RAB9ACTSK | |
| SCHEMBL14396305 | 0.80 | MAOB (0.51) | ATMCTRB1NPC1RAB9ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | CA1 1563/4885ATM 1083/4885CTRB1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.